licaminlimab

Phase 2Monoclonal antibody

OOculis

licaminlimab is one of 34 small molecule programs targeting Eye Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eye DiseaseActive, not recruiting

Dry Eye Disease (DED)Recruiting

Eye DiseasePhase 2

Active, not recruiting

Dry Eye Disease (DED)Preclinical

Recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

2 2

Alphagan

AbbVie

Phase 3

2 3

Chantix

Pfizer

Phase 3

2 4

Zovirax

BBp Consulting, Inc

Phase 3

2 5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 6

Carboxymethylcellulose

AbbVie

Phase 3

4 7

Refresh Plus

AbbVie

Phase 3

1 8

Cenegermin

DDompé Farmaceutici S.p.A

Phase 3

1 9

REFRESH LIQUIGEL

AbbVie

Phase 3

2 10

Refresh Optive

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Dry Eye Disease (DED)

NCT07548632

Clinical

Trials by Indication[1]

Eye Disease1 trial

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

Completed·OOculis·Phase 2·NCT05896670·122 enrolled

Dry Eye Disease (DED)1 trial

A Phase 2b/3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype

Recruiting·OOculis·Preclinical·NCT07548632·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for licaminlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — licaminlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for licaminlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oculis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: OOculis

licaminlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Eye Disease1 trial

Dry Eye Disease (DED)1 trial

References

Drug Info

Quick Facts

Related News